Ultragenyx sells $500M in royalty interest on rare disease drug to Canadian pension plan
Ultragenyx said early Thursday it has sold 30% of its royalty interest from Kyowa Kirin on future sales of the companies’ rare disease drug Crysvita in the US and Canada.
The acquirer is OMERS, one of the largest pension plans in Canada, who purchased the rights for $500 million, with the agreement kicking off with net sales commencing from April 2023.
The drug is approved by the US and its northern neighbor for X-linked hypophosphatemia, or abnormally low levels of phosphate in the blood, and FGF23-related hypophosphatemia in tumor-induced osteomalacia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
